KICVentures Unveils New Investment Opportunities in AxioMed® and NanoFUSE™ Biologics for 2019 at AAOS

Tuesday, February 26, 2019 Press Release
Email Print This Page Comment bookmark
Font : A-A+

KICVentures is seeking investment to prepare two disruptive spine companies, AxioMed LLC and NanoFUSE Biologics LLC, for acquisition in the next 3-5 years.

BOSTON, Feb. 26, 2019 /PRNewswire-PRWeb/ -- KICVentures, a Boston-based private

investment firm leading in healthcare technology, announced today new investment opportunities in two disruptive spine companies will be presented at American Academy of Orthopedic Surgeons (AAOS) in Las Vegas on March 12-16th.

"The spine industry is consolidating as evidenced by multiple acquisitions which creates a favorable opportunity for investors," said Dr. Kingsley R. Chin. "Also favorable is the outlook that consolidation and market expansion will continue for the next 5 years as larger device players respond to growth pressures and to new innovations in the areas of motion preservation and biologics."

KICVentures is seeking investment to prepare two disruptive spine companies, AxioMed and NanoFUSE Biologics LLC, for acquisition in the next 3-5 years.

The AxioMed Freedom™ Disc is a revolutionary cervical and lumbar spinal disc replacement that identically acts like the natural disc because of its patented viscoelastic material. The AxioMed disc has an exclusive 15-year license to the viscoelastic material, robust IP, in-house manufacturing, and manufacturing trade secrets. It is the first and only viscoelastic disc replacement to complete a USA, IDE lumbar clinical study.

The lumbar disc has over 5 years of clinical follow-up data and a USA release is expected in 2020 with the hopes of a lateral indication to compete against NuVasive's lateral fusion. The AxioMed Freedom Cervical Disc, 3-level clinical trials are expected to begin in 2019 and will be the only clinical trial of a cervical viscoelastic disc with multi-level indications.

NanoFUSE Biologics is the only bioactive glass that is FDA-cleared to be combined with DBM. To replicate this one-of-a-kind orthobiologic, the competition would need a clinical IDE study, which gives NanoFUSE a 5-year competitive advantage to start. Bioactive glass has been clinically proven in orthopedics for over 30 years.

"The patented NanoFUSE manufacturing process produces an advanced bioactive glass with high efficacy demonstrated in animal studies," states NanoFUSE President, Jake Lubinski. "We're excited about the growing surgeon adoption of NanoFUSE, as it has been used by over 300 surgeons and implanted in over 1200 patients."

To finance growth, KICVentures has opened a limited number of investment opportunities to qualified investors with a minimum investment of $25,000.

KICVentures will be represented by AxioMed, NanoFUSE and SpineFrontier at Booth #2273 at AAOS.

About KICVentures

KICVentures is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities, and is headquartered in Boston, Mass.

About AxioMed

AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs. AxioMed completed its U.S. IDE for the Lumbar Disc with over five years of clinical follow-up.

About NanoFUSE Biologics

NanoFUSE is the synergistic blend of osteoinductive DBM combined with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in all orthopedic surgery. NanoFUSE Biologics is a KICVentures portfolio company, and is distributed by SpineFrontier.

 

SOURCE KICVentures



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store